Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies
Mutations of <i>RAS</i> oncogenes are responsible for about 30% of all human cancer types, including pancreatic, lung, and colorectal cancers. While <i>KRAS1</i> is a pseudogene, mutation of <i>KRAS2</i> (commonly known as <i>KRAS</i> oncogene) is dire...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/7/3706 |